全文获取类型
收费全文 | 153822篇 |
免费 | 31250篇 |
国内免费 | 2391篇 |
专业分类
耳鼻咽喉 | 5239篇 |
儿科学 | 5556篇 |
妇产科学 | 2578篇 |
基础医学 | 3495篇 |
口腔科学 | 1509篇 |
临床医学 | 26947篇 |
内科学 | 47711篇 |
皮肤病学 | 7512篇 |
神经病学 | 15005篇 |
特种医学 | 6450篇 |
外科学 | 41212篇 |
综合类 | 368篇 |
现状与发展 | 72篇 |
一般理论 | 2篇 |
预防医学 | 7299篇 |
眼科学 | 3407篇 |
药学 | 1120篇 |
中国医学 | 10篇 |
肿瘤学 | 11971篇 |
出版年
2024年 | 685篇 |
2023年 | 4787篇 |
2022年 | 1187篇 |
2021年 | 3080篇 |
2020年 | 6038篇 |
2019年 | 2177篇 |
2018年 | 7401篇 |
2017年 | 7334篇 |
2016年 | 8444篇 |
2015年 | 8425篇 |
2014年 | 15503篇 |
2013年 | 15669篇 |
2012年 | 5543篇 |
2011年 | 5565篇 |
2010年 | 10398篇 |
2009年 | 14283篇 |
2008年 | 5901篇 |
2007年 | 4169篇 |
2006年 | 6604篇 |
2005年 | 3896篇 |
2004年 | 3137篇 |
2003年 | 2119篇 |
2002年 | 2179篇 |
2001年 | 3925篇 |
2000年 | 3123篇 |
1999年 | 3322篇 |
1998年 | 3680篇 |
1997年 | 3501篇 |
1996年 | 3389篇 |
1995年 | 3252篇 |
1994年 | 1974篇 |
1993年 | 1600篇 |
1992年 | 1462篇 |
1991年 | 1530篇 |
1990年 | 1141篇 |
1989年 | 1244篇 |
1988年 | 1086篇 |
1987年 | 917篇 |
1986年 | 931篇 |
1985年 | 764篇 |
1984年 | 596篇 |
1983年 | 554篇 |
1982年 | 542篇 |
1981年 | 430篇 |
1980年 | 384篇 |
1979年 | 348篇 |
1978年 | 363篇 |
1977年 | 421篇 |
1975年 | 299篇 |
1972年 | 341篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
171.
172.
Marc Bischof MD Jürgen Debus Klaus Herfarth Thomas Muley Jutta Kappes Konstantina Storz Hans Hoffmann 《Strahlentherapie und Onkologie》2007,183(12):679-684
PURPOSE: To analyze the effectiveness of surgery and chemotherapy with or without radiotherapy in the management of limited small cell lung cancer (LSCLC) in stages I and II. PATIENTS AND METHODS: 39 patients (median age 62 years) with LSCLC in stages pT1 or pT2 and pN0 or pN1 (stages IA-IIB) who had a tumor resection and systematic lymph node dissection were reviewed retrospectively. The median follow-up period was 29 months. 35 patients (90%) received a median of four cycles of a platinum-containing chemotherapy postoperatively. 16 patients (41%) received an adjuvant thoracic radiotherapy (TRT, median 50 Gy); 21 patients (54%) received a prophylactic cranial irradiation (PCI, median 30 Gy). RESULTS: The median overall survival for all patients was 47 months, resulting in actuarial 1-, 3-, and 5-year survival rates of 97%, 58%, and 49%, respectively. Distant metastases were found in 13 patients (33%) after a median of 16 months. Patients who received an adjuvant TRT showed a trend toward improved thoracic recurrence-free survival (p = 0.06) and improved overall survival (p = 0.07) compared to those treated with surgery and chemotherapy only. Brain metastasis-free survival (p = 0.01) and overall survival (p = 0.01) were improved significantly in patients who received a PCI. CONCLUSION: Surgical tumor resection may be considered for carefully selected patients. Adjuvant chemotherapy and PCI are recommended for all patients. Adjuvant TRT is currently used in patients with positive lymph nodes (pN1), because the probability of a subclinical involvement of the mediastinal lymphatic system appears to be increased in these patients. 相似文献
173.
PURPOSE: The aim of this study is (1) to develop a new method of risk classification for clinically localized prostate cancer; (2) to examine it in terms of compatibility with existing data such as nomograms; and (3) to compare it with existing risk-grouping methods. MATERIAL AND METHODS: The new grading system introduced here consists of three factors. The first is a prostate-specific antigen (PSA) of 4.1-10.0 ng/ml (score 0), 10.1-20.0 ng/ml (score 1), and >20.0 ng/ml (score 2). The second is a Gleason score (GS) of 6 (score 0), 7 (score 1), and 8-10 (score 2). The third is T classifications (UICC 2002) of T1c-T2a (score 0), T2b-T2c (score 1), and T3a (score 2). The sum of the three scores was named Prostate Risk Index (PRIX). Then, the compatibility of PRIX with the Partin Table, Kattan Nomogram, and Roach's formula was examined. At the same time, PRIX was compared with D'Amico, the National Comprehensive Cancer Network (NCCN), and Seattle classifications. RESULTS: PRIX 0 corresponded to 1-2% of pathologic lymph node involvement (pLN+) according to the Partin Table; PRIX 1 to 3-4%; PRIX 2 to 7-10%; PRIX 3 to 14-18%; PRIX 4 to 24-29%; PRIX 5 to 32-37%; and PRIX 6 to 42%. PRIX well separated the risks with relatively narrow ranges of probability, while D'Amico, NCCN, and Seattle classifications generally gave wide ranges especially for high-risk groups, both in the Partin Table and Kattan Nomogram. Roach's formula sometimes overestimated the risk compared to the Partin Table. CONCLUSION: PRIX fully corresponded to the Partin Table in terms of pLN+, and corresponded to the other nomograms better than any existing risk-grouping method. PRIX may thus function as a prognostic factor or contribute to patient selection in clinically localized prostate cancer. 相似文献
174.
Kai-Hang Yiu MBBS Chung-Wah Siu MBBS Chu-Pak Lau MD Kathy L.F. Lee MBBS Hung-Fat Tse MD 《Heart rhythm》2007,4(2):221-223
We report a case of successful transvenous, catheter-based, cavotricuspid isthmus ablation for treatment of atrial flutter using microwave energy. Microwave energy was delivered at 900–930 MHz using 21 W of power. Bidirectional cavotricuspid isthmus conduction block was achieved by microwave ablation without any patient discomfort or complication during the procedure. Our initial experience suggests that transcatheter microwave ablation is feasible for the cure of typical atrial flutter. 相似文献
175.
176.
Four Chinese patients (2 boys, 2 girls), ages 4–9 years, who had episodes of perception error of body schema and objects are reported. The metamorphopsia, which had been named Alice in Wonderland syndrome, is the major presentation. All of them were proved to have acute Epstein-Barr virus infection, as documented by positive heterophil antibody test and/or positive IgM antibody to Epstein-Barr virus capsid antigen. The duration of the perception disorder ranged from 1 week to 3 months. We believe that any young child presenting with Alice in Wonderland syndrome should undergo examination for Epstein-Barr virus infection; complete recovery from the disorder can be expected. 相似文献
177.
178.
179.
180.